Regeneron Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
REGN Regeneron Pharmaceuticals Inc
NSC Norfolk Southern Corp
WM Waste Management Inc
ITOS Iteos Therapeutics Inc
CCLD CareCloud Inc
JEF Jefferies Financial Group Inc
RSASF Resaas Services Inc
VRNT Verint Systems Inc
TRHC Tabula Rasa HealthCare Inc
ILMN Illumina Inc

Health Care : Biotechnology | Large Cap Blend
Company profile

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It also provides Expresse service assurance and CloudCheck WiFi experience management solutions.

Day's Change
-11.06 (-1.42%)
B/A Size
Day's High
Day's Low
(Below Average)

Today's volume of 556,317 shares is on pace to be lower than REGN's 10-day average volume of 724,147 shares.


GE Healthcare Introduces SIGNA Experience: A New Platform of Transformative Technologies that Leverage the Power of AI and Deep-Learning in MRI Scanning

11:40 am ET November 27, 2022 (BusinessWire) Print

GE Healthcare today announced the launch of SIGNA Experience, a platform of four synergistic technologies that help users through the diagnostic journey. This integrated collection works together to ensure the smoothest magnetic resonance imaging (MRI) scanning experience possible for the physician, technologists of all skill levels, and the patient.

SIGNA One is the cornerstone of these solutions: A next generation, imaging software platform supporting an elegant, intuitive user interface, designed to offer high quality magnetic resonance (MR) imaging. AI/Deep-learning solutions: Pioneering, deep-learning AI applications, such as AIR Recon DL for improved signal-to-noise ratio (SNR), image sharpness and shorter scan time. To date, an estimated 5.5 million patients globally have been scanned with AIR Recon DLi. Workflow solutions: Automated, intelligent workflow technologies, that include AIR x and AIRTouch, which guide technologists to help make an MRI scan set up better, faster, and easier. AIR Coils: Industry leading, transformative technology in coils, which are flexible, lightweight, and comfortable, enabling total freedom in coil positioning and handling during an MRI scan.

With operational efficiency the fastest growing challenge for radiology departments, SIGNA One enables greater workflow productivity by requiring only a fraction of the clicks needed to perform an exam from setup to completed scanii. The platform's modern user experience is consistent with common day-to-day interactions individuals have with devices such as computers, phones and tablets, promoting ease of use. The benefits of this user interface are that it enables:

Intuitive workflow for all experience levels and virtually no learning curve. Technologists can keep track of progress at a glance with useful visual reminders, showing them where they are at any point within the scanning process. Efficiency with visually assisted highlighted fields to guide technologists step-by-step, making the process flow easily; and flexibility in design to accommodate for future expansion in AI and workflows. Simplification with an easy-to-use express mode which only requires a few clicks to complete an examination, helping to streamline workflow and optimize throughput. Intelligent automation that highlights the most likely action following a scan.

"Today, we are thrilled to announce a new platform of transforming technologies to complement our exciting MR portfolio," said Jie Xue, President & CEO, Magnetic Resonance, GE Healthcare. "SIGNA Experience was designed in response to today's industry pressures, to help achieve operational efficiency and simplicity, as clinicians face a significant volume of non-urgent backlog scans caused largely by the impact of COVID-19, radiologist shortages & staff burnout, as well as today's growing disease burden. These technologies enable scanner operators of all skill levels to get the job done without compromising quality and output."

SIGNA One is currently commercially available on SIGNA Prime. All other SIGNA Experience solutions are currently commercially available.

About GE Healthcare:

GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 48,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

Follow us on Facebook, LinkedIn, Twitter, Instagram and Insights for the latest news, or visit our website for more information.

____________________ i Calculated by IB data with estimation 20 scans per day, 5.5 working day in a week, fully start using AIR Recon DL 4 weeks after delivery, as of November 2022 ii GE Healthcare data on file

View source version on

SOURCE: GE Healthcare

Maureen Oladipo 
+1 229 418 4479
comtex tracking


Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.